DWTX

#3960
Dogwood Therapeutics, Inc. - Common Stock
2.6 9 USD
+0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
2.62
2.71
Jahresspanne
1.28
3.50
Tagesänderung
+4.26%
Monatliche Änderung
+63.03%
6 month change
-6.11%
Jahresänderung
-10.33%
Vorheriger Schlusskurs
2.5 8
Open
2.6 6
Tief
2.6 2
Hoch
2.7 1
Volumen
117
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Dogwood Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Dogwood Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Dogwood Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Dogwood Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Dogwood Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Dogwood Therapeutics, Inc. current report, Q1 FY2026
8-K

Dogwood Therapeutics, Inc. current report, Q4 FY2025

Full document

Business Context and Reporting Period

Company: Dogwood Therapeutics, Inc. (DWTX)
Filing Type: Form 8-K (Current Report)
Date of Report: November 6, 2025
Reporting Period: Third quarter ended September 30, 2025
Context: The filing serves to announce the results of operations for the third quarter of 2025. The detailed financial data is contained within a press release furnished as Exhibit 99.1, which is incorporated by reference but explicitly stated as not "filed" for purposes of Section 18 of the Exchange Act.

Key Financial Metrics

The provided text is a cover page and index for the Form 8-K. It references the existence of financial results but does not contain the specific numerical data. Consequently, the following metrics are not available in the source text:

  • Revenue: Not provided in the filing text.
  • Profit/Loss: Not provided in the filing text.
  • Cash Flow: Not provided in the filing text.
  • Margins: Not provided in the filing text.
  • Debt and Liquidity: Not provided in the filing text.

Material Changes

The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for this information.

Guidance, Outlook, and Risks

Guidance and Outlook: No specific forward-looking guidance or management commentary is included in the provided text.
Risks and Contingencies: No specific risks or contingencies are detailed in the provided text.
Unusual Items: No unusual items are described in the provided text.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated November 6, 2025) to obtain actual revenue, net loss, and cash position figures for Q3 2025.
  • Verify the company's status as an Emerging Growth Company (indicated as "Yes" in the filing) and its election regarding extended transition periods for accounting standards.
  • Confirm the liquidity runway and cash burn rate, as these are critical for a pre-revenue or early-stage biotech firm like Dogwood Therapeutics, though not explicitly stated in this summary text.
  • Check for any clinical trial updates or regulatory milestones mentioned in the full press release, as these often drive valuation for this sector.